KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression

被引：34

作者：

Zhang, Zining ^{[1
,2
]}

Zhang, Heng ^{[1
,2
]}

Liao, Xiang ^{[1
,2
]}

Tsai, Hsiang-i ^{[1
,2
]}

机构：

[1] Jiangsu Univ, Inst Med Imaging & Artificial Intelligence, Zhenjiang, Peoples R China

[2] Jiangsu Univ, Affiliated Hosp, Dept Med Imaging, Zhenjiang, Peoples R China

来源：

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2023年 / 11卷

基金：

中国国家自然科学基金;

关键词：

PDAC; KRAS mutation; phosphokinase; metabolic reprogramming; therapy resistance; poorer prognosis; MUTANT KRAS; GLUTAMINE-METABOLISM; MOUSE MODEL; CANCER; CELL; INHIBITOR; INITIATION; GLYCOLYSIS; KRAS(G12D); EFFICACY;

D O I：

10.3389/fcell.2023.1147676

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. It has a poor response to conventional therapy and has an extremely poor 5-year survival rate. PDAC is driven by multiple oncogene mutations, with the highest mutation frequency being observed in KRAS. The KRAS protein, which binds to GTP, has phosphokinase activity, which further activates downstream effectors. KRAS mutation contributes to cancer cell proliferation, metabolic reprogramming, immune escape, and therapy resistance in PDAC, acting as a critical driver of the disease. Thus, KRAS mutation is positively associated with poorer prognosis in pancreatic cancer patients. This review focus on the KRAS mutation patterns in PDAC, and further emphases its role in signal transduction, metabolic reprogramming, therapy resistance and prognosis, hoping to provide KRAS target therapy strategies for PDAC.

引用

页数：16

共 160 条

[1] Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy [J].

Abdel-Wahab, Ali F. ;

Mahmoud, Waheed ;

Al-Harizy, Randa M. .

PHARMACOLOGICAL RESEARCH, 2019, 150

[2] Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma [J].

Aguirre, AJ ;

Bardeesy, N ;

Sinha, M ;

Lopez, L ;

Tuveson, DA ;

Horner, J ;

Redston, MS ;

DePinho, RA .

GENES & DEVELOPMENT, 2003, 17 (24) :3112-3126

[3] High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients [J].

Allenson, K. ;

Castillo, J. ;

San Lucas, F. A. ;

Scelo, G. ;

Kim, D. U. ;

Bernard, V. ;

Davis, G. ;

Kumar, T. ;

Katz, M. ;

Overman, M. J. ;

Foretova, L. ;

Fabianova, E. ;

Holcatova, I. ;

Janout, V. ;

Meric-Bernstam, F. ;

Gascoyne, P. ;

Wistuba, I. ;

Varadhachary, G. ;

Brennan, P. ;

Hanash, S. ;

Li, D. ;

Maitra, A. ;

Alvarez, H. .

ANNALS OF ONCOLOGY, 2017, 28 (04) :741-747

[4] A gene-environment-induced epigenetic program initiates tumorigenesis [J].

Alonso-Curbelo, Direna ;

Ho, Yu-Jui ;

Burdziak, Cassandra ;

Maag, Jesper L. V. ;

Morris, John P. ;

Chandwani, Rohit ;

Chen, Hsuan-An ;

Tsanov, Kaloyan M. ;

Barriga, Francisco M. ;

Luan, Wei ;

Tasdemir, Nilgun ;

Livshits, Geulah ;

Azizi, Elham ;

Chun, Jaeyoung ;

Wilkinson, John E. ;

Mazutis, Linas ;

Leach, Steven D. ;

Koche, Richard ;

Pe'er, Dana ;

Lowe, Scott W. .

NATURE, 2021, 590 (7847) :642-648

[5] Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer [J].

Andersen, Dana K. ;

Korc, Murray ;

Petersen, Gloria M. ;

Eibl, Guido ;

Li, Donghui ;

Rickels, Michael R. ;

Chari, Suresh T. ;

Abbruzzese, James L. .

DIABETES, 2017, 66 (05) :1103-1110

[6] Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer [J].

Azizi, Nawab ;

Toma, Jelena ;

Martin, Mickenzie ;

Khalid, Muhammad Faran ;

Mousavi, Fatemeh ;

Win, Phyo Wei ;

Borrello, Maria Teresa ;

Steele, Nina ;

Shi, Jiaqi ;

di Magliano, Marina Pasca ;

Pin, Christopher L. .

ONCOGENE, 2021, 40 (17) :3118-3135

[7] Targeting KRAS in pancreatic cancer: new drugs on the horizon [J].

Bannoura, Sahar F. ;

Uddin, Md. Hafiz ;

Nagasaka, Misako ;

Fazili, Farzeen ;

Al-Hallak, Mohammed Najeeb ;

Philip, Philip A. ;

El-Rayes, Bassel ;

Azmi, Asfar S. .

CANCER AND METASTASIS REVIEWS, 2021, 40 (03) :819-835

[8] Challenges and Opportunities for Pancreatic Cancer Immunotherapy [J].

Bear, Adham S. ;

Vonderheide, Robert H. ;

O'Hara, Mark H. .

CANCER CELL, 2020, 38 (06) :788-802

[9] Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs [J].

Bond, Michael J. ;

Chu, Ling ;

Nalawansha, Dhanusha A. ;

Li, Ke ;

Crews, Craig M. .

ACS CENTRAL SCIENCE, 2020, 6 (08) :1367-1375

[10] Glutamine Anabolism Plays a Critical Role in Pancreatic Cancer by Coupling Carbon and Nitrogen Metabolism [J].

Bott, Alex J. ;

Shen, Jianliang ;

Tonelli, Claudia ;

Zhan, Le ;

Sivaram, Nithya ;

Jiang, Ya-Ping ;

Yu, Xufen ;

Bhatt, Vrushank ;

Chiles, Eric ;

Zhong, Hua ;

Maimouni, Sara ;

Dai, Weiwei ;

Velasquez, Stephani ;

Pan, Ji-An ;

Muthalagu, Nathiya ;

Morton, Jennifer ;

Anthony, Tracy G. ;

Feng, Hui ;

Lamers, Wouter H. ;

Murphy, Daniel J. ;

Guo, Jessie Yanxiang ;

Jin, Jian ;

Crawford, Howard C. ;

Zhang, Lanjing ;

White, Eileen ;

Lin, Richard Z. ;

Su, Xiaoyang ;

Tuveson, David A. ;

Zong, Wei-Xing .

CELL REPORTS, 2019, 29 (05) :1287-+

← 1 2 3 4 5 6 7 8 9 10 →